Having recently been subject to an extensive investigation by the Chinese government, as well as allegations of bribery in Poland, Iraq, Jordan and Lebanon, GlaxoSmithKline plc now faces yet another criminal investigation by the U.K.’s Serious Fraud Office (SFO).
The SFO investigation into GlaxoSmithKline’s commercial practices underscores the reality of multijurisdictional liability. Modern-day companies are often accountable to multiple jurisdictions, and joint investigations and harmonization among prosecutors have become the norm.
Against this backdrop, it increasingly important for companies to effectively implement their compliance programs across their organizations, and to the extent possible, throughout their supply chains.
To read the SFO’s statement regarding the investigation, click here.